The companies will collaborate to hold a global Phase I combination trial of YL201 and Amgen’s Imdelltra for small cell lung ...

Bayer has entered a collaboration with MOMA Therapeutics in which the two companies will advance a small molecule oncology ...

Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

The Phase III trials will evaluate survodutide in metabolic dysfunction-associated steatohepatitis (MASH), fibrosis and ...

The MHRA’s 2024/25 business plan focuses on improving service delivery for its customers, enabling access to new technologies ...

Innovent Biologics and ASK Pharm have signed a strategic partnership for the commercialisation of limertinib for the ...

OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, forming the combined entity ...

The long-acting injectable PrEP option is being rolled out at a record pace in sub-Saharan Africa and lower-income countries.

NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.

The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of ...

The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.

ProductLife Group (PLG) has announced the acquisition of IntiQuan, a Swiss firm specialising in pharmacometrics.